Table 8.
Comparison of data from the literature
| Study | Patients (number) | Major surgical complication rate | Mean age of patients (years) | 30-day mortality rates | Neurologic function improvement rate | Median survival (months) | Prognostic factors | Minimal followup (months) |
|---|---|---|---|---|---|---|---|---|
| Wise et al. [60] | 80 | 13.8% | 56 | 5.7% | 97% | 15.7 | NR | 5 |
| Weigel et al. [57] | 76 | 19% | 59 | 2.6% | 58% | 13.1 | NR | 6 |
| Tomita et al. [52] | 67 | NR | 56 | NR | 74% | NR | Primary tumors; visceral metastases; bone metastases | NR |
| Finkelstein et al. [13] | 987 | 27% | 60 | 9% | NR | 7.6 | Increasing age; male sex; primary tumors | NR |
| North et al. [37] | 61 | 8.2% | 52 | 3.3% | 88% | 10 | Primary tumors; preoperative neurologic status | |
| Jansson & Bauer [26] | 282 | 20% | 66 | 13% | 70% | 6 | NR | 3 |
| Leithner et al. [31] | 69 | NR | 60 | NR | NR | 10 | Primary tumor; visceral metastases | 12 |
| Chaichana et al. [8] | 114 | 17% | 58 | 3% | NR | 7 | NR | 10.8* |
| Wibmer et al. [59] | 62 | NR | 60 | NR | NR | 10.6 | Systemic therapy; primary tumors; visceral metastases | 12 |
| Arrigo et al. [3] | 200 | 34% | 59 | 3% | NR | 8.0 | Charlson comorbidity index; preoperative ambulatory status; primary tumors | NR |
| Current study | 92 | 22.8% | 68 | 3.4% | 78% | 15 | Primary tumors; Tokuhashi score | 6 |
* Mean followup; NR = not reported.